Clinical Trial: A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

Sponsor and Collaborators
University of South Alabama
NewLink Genetics Corporation

Contact
Marion Long, RN
251-665-8000
[email protected]

Contact: Pam Francisco, CCRP
251-665-8000
[email protected]

Principal Investigator
Adam I Riker, MD
USA Mitchell Cancer Institute
 
Clinical Trials.gov Identifier
NCT00746746